Stifel Nicolaus Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA)

Investment analysts at Stifel Nicolaus started coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report issued to clients and investors on Friday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $49.00 price target on the stock. Stifel Nicolaus’ target price points to a potential upside of 88.17% from the company’s previous close.

Several other equities analysts also recently issued reports on the stock. Leerink Partners initiated coverage on shares of Oruka Therapeutics in a report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price target for the company. TD Cowen assumed coverage on Oruka Therapeutics in a report on Monday, September 16th. They issued a “buy” rating on the stock. HC Wainwright started coverage on Oruka Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $45.00 price target on the stock. Wedbush started coverage on Oruka Therapeutics in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $40.00 price objective for the company. Finally, Lifesci Capital began coverage on Oruka Therapeutics in a report on Monday, September 16th. They set an “outperform” rating and a $41.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Price Performance

Shares of ORKA opened at $26.04 on Friday. Oruka Therapeutics has a 12 month low of $18.72 and a 12 month high of $53.88. The stock has a market cap of $31.51 million, a price-to-earnings ratio of -4.34 and a beta of 0.89.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($25.92) EPS for the quarter. As a group, sell-side analysts anticipate that Oruka Therapeutics will post -1.62 earnings per share for the current fiscal year.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.